← Leaderboards
Margaret A Keller
La Biomed Res Inst/ Harbor Ucla Med Ctr
$2,116,833
Attributed
$2,116,833
Total exposure
16
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $224.9K · FY2005–10$250K$187.5K$125K$62.5K$0
'05
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$2,116,833 · 16
By mechanism
M01$1,734,865 · 15
R21$381,968 · 1
Top collaborators
No co-investigators on record.
Most similar at La Biomed Res Inst/ Harbor Ucla Med Ctr
Same institution · by research overlap
- Sheng-Xing Ma$3,697,833
- Thomas M Ernst$23,754,146
- Linda Chang$37,819,216
- David L Rimoin$8,381,773
- Gildon N Beall$1,671,738
Others in their field
Top investigators on “Hiv Infections”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,259,079
- Lawrence Corey · Fred Hutchinson Cancer Center$728,701,834
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$467,263,656
- Judith S. Currier · University Of California Los Angeles$466,447,923
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
Research focus
Hiv InfectionsClinical ResearchHuman Therapy EvaluationAids TherapyHuman SubjectHuman Pregnant SubjectVertical TransmissionCombination ChemotherapyFemaleDrug Screening /EvaluationProtease InhibitorAntiaids AgentZidovudineLamivudineNevirapineDrug Adverse EffectCommunicable Disease ControlClinical Trial Phase IBirthReverse Transcriptase InhibitorsDosagePharmaceutical PreparationsAnti-Retroviral AgentsPharmacokinetics
Grant awards (35)
INTENSIVE PHARMACOKINETIC STUDIES OF ANTIRETROVIRAL DRUG COMBINATIONS HIV$8,564
M01 · FY2010 · RR · contact PI
Two-Dimensional 3 Tesla MRS of the Brain in HIV- Infected Youth$206,777
R21 · FY2009 · NS · contact PI
INTENSIVE PHARMACOKINETIC STUDIES OF ANTIRETROVIRAL DRUG COMBINATIONS$18,159
M01 · FY2009 · RR · contact PI
Two-Dimensional 3 Tesla MRS of the Brain in HIV- Infected Youth$175,191
R21 · FY2008 · NS · contact PI
PHARMACOKINETIC PROPERTIES OF ANTIRETROVIRAL THERAPY DURING PREGNANCY$7,388
M01 · FY2007 · RR · contact PI
PREVALENCE OF MORPHOLOGIC AND METABOLIC ABNORMALITIES IN VERTICALLY HIV-INFEC$10,264
M01 · FY2006 · RR · contact PI
MONTHER-INFANT RAPID INTERVENTION AT DELIVERY (MIRIAD)$8,473
M01 · FY2005 · RR
EFFECT OF ANTIRETROVIRAL THERAPY ON BODY COMPOSITION IN HIV-INFECTED CHILDREN$4,037
M01 · FY2005 · RR
RANDOMIZED TRIAL OF PROTEASE INHIBITOR-INCLUDING VS. PRO$3,908
M01 · FY2004 · RR
EFFECT OF ANTIRETROVIRAL THERAPY ON BODY COMPOSITION IN HIV-INFECTED CHILDREN$2,334
M01 · FY2004 · RR
ACTG353 ORAL NELFINAVIR CO ADMINISTERED W/ ZIDOVUDINE &LAMIVUDINE IN$237,978
M01 · FY2001 · RR
PHASE III RANDOMIZED DOUBLE BLIND CONTROLLED STUDY OF HYPERIMMUNE ANTI HIVG$237,978
M01 · FY2001 · RR
ACTG353 ORAL NELFINAVIR W/ ZIDOVUDINE&LAMIVUDINE IN HIV+ PREGNANT WOM$237,978
M01 · FY2001 · RR
ACTG382 PHARMACOKINETICS, SAFETY, TOLERABILITY&ANTIVIRAL ACTIVITY OF$237,978
M01 · FY2001 · RR
ACTG250 NEVIRAPINE IN HIV 1 INFECTED PREGNANT WOMEN&NEONATES BORN TO$237,978
M01 · FY2001 · RR
ACTG300 COMBINED ZIDOVUDINE LAMIVUDINE VS BETTER OF DDI MONOTHERAPY V$237,978
M01 · FY2001 · RR
ACTG316 NEVIRAPINE VS NEVIRAPINE PLACEBO FOR PREVENTION OF MATERNAL F$237,978
M01 · FY2001 · RR
PHASE III RANDOMIZED DOUBLE BLIND CONTROLLED STUDY OF HYPERIMMUNE ANTI HIVG$982
M01 · FY2000 · RR
ACTG353 ORAL NELFINAVIR W/ ZIDOVUDINE&LAMIVUDINE IN HIV+ PREGNANT WOM$982
M01 · FY2000 · RR
ACTG382 PHARMACOKINETICS, SAFETY, TOLERABILITY&ANTIVIRAL ACTIVITY OF$982
M01 · FY2000 · RR
ACTG250 NEVIRAPINE IN HIV 1 INFECTED PREGNANT WOMEN&NEONATES BORN TO$982
M01 · FY2000 · RR
ACTG300 COMBINED ZIDOVUDINE LAMIVUDINE VS BETTER OF DDI MONOTHERAPY V$982
M01 · FY2000 · RR
ACTG316 NEVIRAPINE VS NEVIRAPINE PLACEBO FOR PREVENTION OF MATERNAL F$982
M01 · FY2000 · RR
ACTG316--Nevirapine vs nevirapine placebo for the prevention of maternal fetal tr$0
M01 · FY2000 · RR
ACTG316--Nevirapine vs nevirapine placebo for the prevention of maternal fetal tr$0
M01 · FY2000 · RR
ACTG316--Nevirapine vs nevirapine placebo for the prevention of maternal fetal tr$0
M01 · FY2000 · RR
ACTG353 ORAL NELFINAVIR CO ADMINISTERED W/ ZIDOVUDINE &LAMIVUDINE IN$0
M01 · FY2000 · RR
ACTG353 ORAL NELFINAVIR CO ADMINISTERED W/ ZIDOVUDINE &LAMIVUDINE IN$0
M01 · FY2000 · RR
ACTG353 ORAL NELFINAVIR CO ADMINISTERED W/ ZIDOVUDINE &LAMIVUDINE IN$0
M01 · FY2000 · RR
ACTG316 NEVIRAPINE VS NEVIRAPINE PLACEBO FOR PREVENTION OF MATERNAL F$0
M01 · FY2000 · RR
ACTG316 NEVIRAPINE VS NEVIRAPINE PLACEBO FOR PREVENTION OF MATERNAL F$0
M01 · FY2000 · RR
ACTG382 PHARMACOKINETICS, SAFETY, TOLERABILITY&ANTIVIRAL ACTIVITY OF$0
M01 · FY2000 · RR
ACTG382 PHARMACOKINETICS, SAFETY, TOLERABILITY&ANTIVIRAL ACTIVITY OF$0
M01 · FY2000 · RR
ACTG353 ORAL NELFINAVIR W/ ZIDOVUDINE&LAMIVUDINE IN HIV+ PREGNANT WOM$0
M01 · FY2000 · RR
ACTG353 ORAL NELFINAVIR W/ ZIDOVUDINE&LAMIVUDINE IN HIV+ PREGNANT WOM$0
M01 · FY2000 · RR